

## REMARKS

In response to an Office Action of January 29, 2004, original claims 1-18, 21-25, and 27-30 were elected for prosecution by the Applicants. This RCE application respectfully requests consideration of amended claims 21-25, 27-30 and new claims 31-37, which have not been fully and finally substantively examined. The pending claims are drawn to the use of a third binding moiety produced by a transgenically produced multivalent polypeptide. Claims 21-25 and 27-30 are amended herein. Claims 1-20, and 26 are cancelled herein. New claims 31-37 are added. Consideration of the claims 21-25, 27-30 and 31-37 is requested.

New claims 31 through 37, being dependent upon and further limiting independent amended claims 21 and 27 (as the case may be), should also be allowable for that reason, as well as for the additional recitations they contain. Applicants respectfully request favorable consideration of these new claims in view of the above amendments and remarks.

The Commissioner is authorized to charge any fee which may now or hereafter be due for this application to GTC Biotherapeutics' Deposit Account No. 502092.


Applicants respectfully submit that the pending claims of this Amendment are in condition for allowance, and that this case is now in condition for allowance of all pending claims. Such action is thus respectfully requested. If the Examiner disagrees, or believes for any other reason that direct contact with Applicant's attorney would advance the prosecution of the case to finality, the Examiner is invited to telephone the undersigned at the number given below.

Early and favorable action is earnestly solicited.

Respectfully Submitted,

Date: 12/20/07

By: \_\_\_\_\_

  
Byron V. Olsen, Reg. No. 42,960  
**ATTORNEY FOR APPLICANTS**  
GTC Biotherapeutics, Inc.  
175 Crossing Blvd., Suite 410  
Framingham, MA 01702  
Tel. # (508) 370-8150  
Fax # (508) 370-3797